In a nutshell This study investigated if treating patients who have prostate cancer with androgen receptor inhibitors (ARIs) increased their risk of falling and breaking their bones. The study found that patients who received ARI were more likely to have a fall or fracture compared to other treatments. Some background Prostate cancer (PCa)...
Read More
In a nutshell This study assessed whether olaparib (Lynparza) affected progression-free survival (PFS; survival without cancer worsening) in patients with metastatic castration-resistant prostate cancer (mCRPC) and certain genetic mutations (abnormalities). The study found that olaparib improved PFS in these patients. Some...
Read More
In a nutshell This study examined the effectiveness of cabazitaxel (Jevtana) in patients with prostate cancer that has spread. This study concluded that cabazitaxel improved patient outcomes more than conventional hormone therapy. Some background Androgen deprivation therapy (ADT) remains a standard treatment for patients with prostate cancer....
Read More
In a nutshell The aim of this study was to determine whether the neutrophil to lymphocyte ratio (NLR) can be used to determine outcome in CRPC patients treated with enzalutamide (Xtandi). It was concluded that NLR could be used to predict the outcome for CRPC patients treated with enzalutamide. Some background Treatment for metastatic...
Read More
In a nutshell This study examined the effects of enzalutamide (Xtandi) in improving disease-related symptoms associated with advanced metastatic prostate cancer. The researchers concluded that enzalutamide treatment is effective in managing prostate cancer-derived bone tumors and pain among men with advanced prostate cancer. Some background When...
Read More
In a nutshell The authors reviewed the benefit of enzalutamide (Xtandi) in treating advanced hormone-resistant (castration-resistant) prostate cancer. Some background Hormone therapy is a common treatment used in prostate cancer. It targets the male sex hormones active in prostate cancer, such as testosterone. Some patients...
Read More
In a nutshell The authors interpreted the results of a phase III trial on the use of enzalutamide (Xtandi) in treating patients with metastatic (cancer that has spread) hormone-resistant (castration-resistant) prostate cancer. Some background Hormone therapy is a common treatment used in prostate cancer. It targets the male sex hormones...
Read More
In a nutshell This clinical trial evaluated the survival benefits of a drug named Enzalutamide (Xtandi) for patients with non-responsive (refractory) advanced prostate cancer previously treated with chemotherapy. Main findings: Enzalutamide prolonged survival by approximately 5 months and reduced the risk of death by 37%. Some background The...
Read More
